Submit PA ≥2 weeks with complete clinical and imaging documentation

Submit prior-authorization at least two weeks before an elective procedure and include documentation of: the proposed procedure matching clinical need; the condition being treated; detailed prior provider-directed conservative therapy (duration, frequency, response); prior interventions and response; aneurysm location/size if present; nature of critical limb ischemia (non-healing wound or ischemic rest pain) when applicable; and recent (within 6 months) diagnostic imaging reports and clinical evaluation (e.g., ABIs, duplex, CTA/MRA, angiogram, IVUS, symptoms, physical exam, ulcer details).

• Prior-authorization requests should be submitted at least two weeks prior to an elective surgery.
• Include recent (within 6 months) imaging reports (duplex, CTA/MRA/angiogram/IVUS) and clinical evaluation documenting symptoms and exam (e.g., ulcer size/location).
• Provide detailed conservative therapy history and prior procedural history with responses.

Facility/operator competency and embolic protection expectations for CAS/TCAR

Ensure carotid stenting (CAS/TCAR) is performed in facilities that meet CMS competency expectations — documented physician training, facility support, and outcome data collection — and use embolic protection when indicated.

• CAS with embolic protection should be performed in facilities competent in evaluation, procedure, and follow-up per CMS standards.
• Maintain documentation of physician training, facility support, and outcomes data as applicable.

PA required for iliac branched endograft (CPT 34717) — document concurrent AAA and size criteria

Obtain prior authorization when billing iliac branched endograft (CPT 34717) and related iliac endovascular repair codes; clinical documentation must meet the CPT 34717 medical necessity criteria (concurrent AAA repair planned, ipsilateral common iliac aneurysm >3.5 cm, and contralateral IIA occlusion).

• CPT 34717 requires documentation that AAA repair is planned concurrently, ipsilateral common iliac aneurysm >3.5 cm, and contralateral internal iliac artery occlusion.
• Prior authorization must be submitted with imaging and clinical history supporting those criteria.

Obtain PA using the specific CPT code(s) for peripheral vascular interventions

Request prior authorization for the listed non-coronary peripheral vascular CPT codes relevant to the planned procedure and include procedure-specific imaging and clinical indication in the request.

• Prior authorization is tied to specific CPT codes for non-coronary peripheral vascular interventions; submit the specific code(s) planned with supporting imaging and clinical rationale.
• Examples of covered code families include femoral/popliteal angioplasty/stent (e.g., 37263–37269) and atherectomy (37271–37273).

Include listed CPT and HCPCS codes (e.g., IVL C-codes) in PA request

Follow payer prior-authorization processes for the listed revascularization CPT codes and intravascular lithotripsy HCPCS codes; request authorization using the applicable CPT/HCPCS (e.g., 37271–37299, C9764–C9775) when indicated.

• Prior authorization is relevant for the listed revascularization CPT codes (e.g., 37271–37299).
• Intravascular lithotripsy HCPCS codes (C9764–C9775) should be included in PA requests when IVL is planned.

Authorization must include failed conservative therapy, surveillance data, and lesion-specific imaging

Include evidence required to support authorization: failed conservative therapy for claudication (3 months), surveillance data (ABI drop, duplex PSV/velocity ratios), and imaging confirming lesion-specific thresholds (e.g., ≥50% stenosis); inframalleolar cases require documentation of active tissue loss and lack of distal flow or PAT >225 ms.

• For claudication, document a failed 3‑month trial of provider-directed conservative therapy and imaging confirming ≥50% stenosis.
• For repeat intervention provide surveillance triggers (ABI drop ≥0.15, duplex PSV thresholds, ≥50% imaging stenosis).
• Inframalleolar interventions require active tissue loss and imaging showing occluded distal vessels or PAT >225 ms.

PA required for endovenous ablation — document CEAP/VCSS and qualifying duplex within 6 months

Obtain prior authorization for endovenous ablation and related saphenous vein procedures; include documentation of symptomatic venous disease (CEAP ≥ C2 or VCSS ≥6) and a venous duplex completed within 6 months demonstrating pathologic truncal vein reflux (≥500 ms) per segment-specific rules.

• Document CEAP classification ≥ C2 or VCSS ≥6 and symptoms attributable to venous disease.
• Submit recent venous duplex (within 6 months) showing truncal vein reflux ≥500 ms with required segment counts (e.g., ≥2 segments for above-knee GSV).

PA required for non‑compounded foam sclerotherapy (CPT 36465, 36466)

Prior authorization is required per payer processes for non-compounded foam sclerotherapy codes: CPT 36465 (single incompetent truncal vein) and CPT 36466 (multiple truncal veins, same leg).

• Use CPT 36465 for injection of non-compounded foam sclerosant to a single truncal vein.
• Use CPT 36466 for multiple truncal veins in the same extremity; include required clinical and duplex documentation in the PA.

Include procedure-specific CPT codes and supporting evidence for venous/open procedures

When requesting authorization for saphenous trunk, tributary, perforator, phlebectomy, or open ligation/stripping procedures, submit the specific CPT codes listed and supporting clinical/imaging evidence demonstrating medical necessity.

• Examples of codes include 36468, 36470–36471, 37700, 37718, 37722, 37735, 37760–37766, 37780, 37785, 37799.
• Include duplex results, CEAP/VCSS, and history of prior conservative or ablation therapy as applicable.

PA required for venous stent/angioplasty codes (e.g., 37238, 37248) with imaging and conservative therapy documentation

Prior authorization applies to venous stent and angioplasty CPT codes (e.g., 37238, 37239, 37248, 37249); include imaging and clinical criteria demonstrating indication (e.g., ≥50% area reduction or >60% diameter stenosis for iliac/IVC lesions, failed conservative therapy for 8 weeks when applicable).

• CPT 37238/37239 for venous stent placement and CPT 37248/37249 for venous angioplasty require PA per payer process.
• Support PA with IVUS/venogram/CT/MR demonstrating stenosis thresholds and documentation of failed conservative therapy when required.

PA for hemodialysis outflow angioplasty/stenting — document clinical dialysis-related criteria

For hemodialysis outflow procedures (e.g., CPT 37238, 37248) request prior authorization when clinical criteria for outflow obstruction are present (ipsilateral arm edema, inadequate dialysis performance, loss of thrill, large collaterals) and when stenting criteria (recurrent >50% stenosis within 3 months, elastic recoil, pseudoaneurysm coverage) apply.

• Document clinical signs of outflow obstruction (arm edema, dialysis recirculation, inability to achieve target blood flow, prolonged bleeding, loss of thrill).
• Stenting indications include symptomatic recurrent >50% stenosis within 3 months of angioplasty or elastic recoil with residual >50% stenosis.

PA required for embolization — include indication‑specific imaging and specialist documentation

Prior authorization is expected for embolization procedures; the request must reference the specific clinical indication and supporting imaging or specialist documentation (e.g., size criteria for visceral aneurysms, failure of conservative therapy for genicular embolization, anoscopy for hemorrhoids).

• Provide diagnostic imaging and indication-specific documentation (CTA/MRA/US/angiogram for aneurysm sizes; specialist referral notes for joint embolization).
• For hemorrhoid embolization include anoscopy confirmation of recurrent bleeding or documentation of failed nonsurgical therapy.

Preauthorize the single embolization CPT code matching the primary intent (37241–37244); document separate fields

Select and preauthorize the single CPT embolization code that corresponds to the primary clinical intent and vessel type (e.g., CPT 37241–37244); if multiple distinct anatomical treatment fields are performed, document them separately to allow independent reporting.

• Coding selection should be driven by the dominant therapeutic intent (venous malformations 37241; arterial non-hemorrhage 37242; tumor/organ ischemia 37243; hemorrhage 37244).
• When multiple separate anatomical areas are treated, document separate operative fields clearly to permit reporting of each area.

Accurate embolization CPT selection (37241–37244) required to support PA and avoid audit

Ensure embolization coding accuracy: use the appropriate CPT code (37241–37244) that matches the billed procedure and primary intent to support authorization and claims processing; incorrect coding may trigger audit or denial.

• Use CPT 37241 for venous malformations/varices/varicoceles; 37242 for arterial embolization other than hemorrhage/tumor; 37243 for tumor/organ ischemia; 37244 for hemorrhage control.
• Only one primary embolization code per treatment field should be reported; document intent and vessel type in the PA.

Urgent/emergent requests: document condition and imaging; conservative therapy not required

For urgent or emergent clinical indications (e.g., critical limb ischemia, symptomatic carotid stenosis, crescendo TIAs, symptomatic or ruptured aneurysms), emergent requests may be processed without prior conservative management; document urgency and supporting imaging/clinical evidence per NCQA standards.

• Provider-directed non-surgical management is not required when documentation supports urgent/emergent conditions such as critical limb ischemia or symptomatic carotid stenosis.
• Follow NCQA urgent/emergent determination criteria and include supporting imaging/clinical assessment in the request or retrospective documentation as applicable.

Vertebral artery stenting requires prior medical therapy failure and symptom/imaging correlation

For extracranial vertebral artery stenting document failure of antiplatelet or anticoagulation therapy, exclusion/management of non-vascular etiologies, and ongoing posterior circulation symptoms; authorization is indicated only after these prerequisites are met.

• Document prior medical therapy failures (antiplatelet/anticoagulation) and exclusion of non-vascular causes.
• Provide imaging demonstrating 60–99% extracranial vertebral artery stenosis and correlate with clinical symptoms.

Document intraoperative treatment escalation and clinical rationale in operative report

Document intraoperative rationale when treatment is escalated (e.g., additional levels treated) due to operative findings; include intraoperative notes describing the decision-making and that additional levels were necessary.

• If intraoperative findings change the planned procedure, include operative report details explaining the escalation.
• Document why additional levels or devices were required to support claims and authorization adjudication.

Require 3‑month trial of provider‑directed conservative therapy for claudication prior to PA

For claudication, document a trial of at least 3 months of provider-directed conservative therapy (including structured exercise program if available) with documented follow-up prior to authorization for intervention.

• Conservative therapy must be documented with duration, modalities attempted, and clinical response.
• If structured exercise programs are unavailable locally, document provider-directed exercise counseling and follow-up.

Document prior conservative venous management and symptom attribution before PA

Expect conservative management attempts for venous disease where appropriate (e.g., compression, elevation, exercise) and document symptom persistence and why intervention is clinically indicated rather than cosmetic.

• Document that symptoms are attributable to venous disease (not cosmetic) and conservative measures were attempted when applicable.
• Include CEAP/VCSS scores and duplex results to correlate symptoms with pathology.

Document valid justification for staged procedures (contrast >200 mL, instability, excess fluoroscopy, anesthesia limits)

When staging procedures, document valid justification in the medical record (e.g., patient instability, excess fluoroscopy, need to convert to general anesthesia with unavailable resources, or contrast volume >200 mL); absent valid justification, staged procedures may be denied.

• Valid reasons for staging include patient instability, fluoroscopy exceeding safe dosage, unavailable anesthesia resources for conversion, or contrast volume >200 mL.
• Document the justification clearly in the medical record to support staged treatment.

Require failed 8‑week conservative trial before iliac vein stenting (unless urgent post‑thrombolysis indication)

Iliac vein interventions require documentation of failure of an 8‑week trial of conservative therapy (graded compression, weight loss if applicable) prior to stenting for non-thrombotic lesions unless urgent indications (e.g., post-thrombolysis residual stenosis) are present.

• Record duration and modalities of conservative therapy and objective lack of improvement before PA for NIVL.
• If urgent/acute post-thrombolysis residual stenosis (≥50%) exists, document the urgency to bypass the conservative trial requirement.

Trial of conservative therapy for non‑malignant SVC syndrome required prior to intervention

For non-malignant SVC syndrome, document failure of conservative therapy (elevation, diuretics, anticoagulation) before angioplasty/stenting; for malignant SVC syndrome, palliative interventions may proceed per clinical need.

• Document conservative measures attempted and their lack of symptomatic resolution for non-malignant SVC syndrome.
• Palliative stenting for malignancy is allowable with appropriate documentation.

Require ≥3 months failed conservative therapy for joint-related embolization prior to PA

For musculoskeletal/joint embolization (e.g., genicular, shoulder), document failure of specified conservative therapies (typically ≥3 months) or prior procedure attempts before authorization is considered.

• Genicular embolization requires failure of ≥3 months of conservative therapy and appropriate pain/function scores (VAS ≥55 or WOMAC ≥40) when applicable.
• Shoulder embolization for adhesive capsulitis requires ≥3 months conservative therapy failure and confirmatory exam/imaging.

Require failed prior conservative therapy for hemorrhoid embolization and PAE; include anoscopy/AUA/prostate size evidence

Embolization for hemorrhoids or PAE should be requested only after failure or intolerance of prior nonsurgical therapies (e.g., dietary/lifestyle changes, medical therapy for BPH); include documentation of prior attempts and indication-specific findings (anoscopy for hemorrhoids, AUA score/prostate size for PAE).

• For hemorrhoid embolization include evidence of failed non-surgical treatment and anoscopic confirmation of bleeding when indicated.
• For PAE, document failure/intolerance of medical therapy and prostate metrics (AUA score ≥20 or prostate size ≥50 cm3) per criteria.

Required documentation checklist for PVI prior-authorization

Submit prior-authorization for peripheral vascular intervention (PVI) requests with documentation showing the proposed procedure, condition treated, detailed prior conservative treatment and response, prior interventions and response, aneurysm location/size if present, nature of CLI (non-healing wound or ischemic rest pain), and recent (within 6 months) diagnostic imaging and clinical evaluation.

• Include imaging reports (duplex, CTA/MRA/angiogram/IVUS) completed within 6 months and clinical notes documenting symptoms and exam (ulcer size/location if present).
• Provide a clear description of prior conservative measures and objective response.

Document method and percent of arterial stenosis (NASCET/duplex/CTA/MRA) correlated with symptoms

Document the arterial stenosis measurement method and percent (angiogram, CTA, carotid duplex, or MRA) and correlate the imaging with symptoms or recurrent stenosis status (e.g., NASCET ≥70% for asymptomatic CEA within 6 months; ≥50% for symptomatic CEA).

• State imaging modality and measurement method (NASCET when applicable) and include the percent stenosis.
• Correlate imaging findings with clinical symptoms or recurrent restenosis thresholds (duplex PSV values for carotid restenosis).

Document clinical history that meets procedure-specific criteria (e.g., CPT 34717 concurrent AAA and size requirements)

Clinical history must explicitly document the criteria supporting the chosen procedure (e.g., planned simultaneous AAA repair when requesting CPT 34717; common iliac aneurysm >3.5 cm or internal iliac aneurysm ≥3.0 cm when applicable).

• For CPT 34717 document concurrent AAA repair planning, ipsilateral common iliac aneurysm >3.5 cm, and contralateral IIA occlusion.
• For isolated internal iliac aneurysm treatment document aneurysm ≥3.0 cm if asymptomatic or any symptomatic aneurysm or evidence of bleeding.

Include diagnostic imaging documenting aneurysm size and symptom‑specific findings for aneurysm PA

Provide diagnostic imaging (US, CT, MRI, CTA, MRA or angiogram) documenting aneurysm size and, for symptomatic popliteal aneurysms, include evidence of mural thrombus and new onset claudication, CLI, or blue toe syndrome to support authorization.

• For popliteal aneurysm: imaging showing diameter ≥2.0 cm (asymptomatic) or ≥1.5 cm with mural thrombus plus ischemic symptoms (symptomatic pathway).
• For visceral aneurysms include CTA/MRA/US/angiogram measurements meeting vessel-specific thresholds (e.g., hepatic ≥2.0 cm; splenic ≥3.0 cm or any size in child-bearing potential).

Document condition‑specific findings for brachiocephalic PTA/stent authorization

For brachiocephalic artery interventions include condition‑specific findings (e.g., symptomatic subclavian steal with episodic dizziness, advanced imaging showing high‑grade proximal subclavian stenosis, and duplex evidence of vertebral flow reversal) in the authorization submission.

• Document symptoms, advanced imaging demonstrating high‑grade stenosis or occlusion, and duplex confirmation (e.g., vertebral flow reversal) when applicable.
• Include objective evidence of ischemia or non-healing tissue when treating arm ischemia or ulcers.

Required clinical documentation: symptom-location correlation and objective imaging (≥50% stenosis; PAT >225 ms when inframalleolar)

Clinical notes must document symptoms consistent with lesion location, prior conservative therapy for claudication, and objective imaging confirming location and degree of stenosis (e.g., ≥50%); inframalleolar interventions require imaging showing lack of distal flow or PAT >225 ms.

• Correlate symptoms to lesion location (aorto‑iliac vs superficial femoral vs popliteal) and provide imaging demonstrating ≥50% stenosis.
• For inframalleolar cases include GLASS P2 descriptors, occluded distal vessels on CTA/MRA/angiogram or duplex showing lack of flow, or PAT >225 ms.

Submit venous duplex within 6 months showing truncal reflux ≥500 ms and absence of ipsilateral DVT

A venous duplex study completed within 6 months must be submitted showing required reflux measurements for saphenous/truncal veins (≥500 ms per segment rules) and absence of ipsilateral acute DVT or chronic multisegmental femoral‑popliteal occlusion.

• Submit duplex completed within 6 months documenting ≥500 ms truncal reflux with the segment-specific requirements (e.g., ≥2 segments for above‑knee GSV).
• Confirm absence of ipsilateral acute DVT or chronic multisegmental femoral‑popliteal occlusion.

PA documentation for perforator treatment: duplex (≥500 ms, ≥3.5 mm), CEAP/VCSS, and saphenous status

For perforator treatment near an active ulcer submit a recent venous duplex (within 6 months) documenting perforator reflux ≥500 ms AND vein diameter ≥3.5 mm, CEAP/VCSS to demonstrate symptom severity, and confirmation that saphenous veins draining the ulcer have been treated or are not pathologic.

• Provide duplex demonstrating perforator incompetence (reflux ≥500 ms and diameter ≥3.5 mm) adjacent to the active ulcer.
• Include CEAP or VCSS scores and documentation of prior saphenous vein treatment or absence of saphenous reflux.

Require recent duplex (≤6 months) showing ≥500 ms reflux and CEAP/VCSS documentation for venous PA

A venous duplex ultrasound within 6 months demonstrating required reflux criteria (≥500 ms in specified segments or diameter thresholds for perforators/tributaries) and clinical documentation of CEAP ≥ C2 or VCSS ≥6 are required for authorization of venous procedures.

• Duplex recency must be within 6 months and show required reflux thresholds (≥500 ms) per vein/segment.
• Include CEAP classification or VCSS to document symptom severity and relationship to venous disease.

Document CEAP/VCSS, attributable symptoms, and qualifying imaging within 6 months for venous PA

Providers must document clinical classification (CEAP C2+ or VCSS ≥6), symptoms attributable to venous disease, and imaging (venous duplex or other specified imaging) performed within 6 months showing required reflux, vein diameters, or stenosis measurements to support authorization.

• CEAP C2+ or VCSS ≥6 should be recorded in the clinical documentation.
• Include imaging within 6 months showing required physiologic and anatomic thresholds (reflux ≥500 ms; varicosity/tributary size thresholds; iliac/IVC stenosis thresholds where applicable).

Provide imaging demonstrating required stenosis/diameter thresholds and correlate with clinical signs

Imaging documentation (venogram, IVUS, CT/MR/ultrasound) demonstrating specified degrees of stenosis or vein diameters and clinical signs/symptoms relevant to the indication (e.g., arm edema, venous claudication, inadequate dialysis performance, lifestyle‑limiting SVC symptoms) is required to support medical necessity and authorization.

• Use modality-appropriate measurements (IVUS/venography for area reduction or diameter stenosis; duplex/CTA/MRA for arterial stenosis percentages).
• Correlate imaging findings with clinical manifestations (e.g., dialysis dysfunction, edema, ulceration, SVC symptoms).

Submit CTA/MRA/US/angiogram documenting visceral aneurysm size to meet PA thresholds

Diagnostic imaging (CTA, MRA, US, angiogram) is required to demonstrate visceral artery aneurysm or pseudoaneurysm and to measure size thresholds that meet coverage criteria (e.g., hepatic ≥2.0 cm, splenic ≥3.0 cm or any size in child‑bearing potential, renal ≥3.0 cm).

• Include imaging modality and measured aneurysm diameter in the PA submission.
• Document any symptomatic features or evidence of bleeding when present.

Document primary clinical intent and separate anatomical fields for multi‑area procedures

Document the primary clinical intent and anatomic treatment fields in the authorization request; when multiple anatomical areas are treated document them as separate operative fields to allow independent reporting.

• State the dominant therapeutic intent for embolization coding selection (hemorrhage control, tumor ischemia, venous malformation, etc.).
• When treating multiple distinct anatomical areas provide clear documentation distinguishing each operative field.

Follow coding guidance: select correct embolization CPT (37241–37244) that matches documented intent

Use the correct embolization CPT codes (37241–37244) per coding guidance in PA requests to avoid billing issues; ensure the code selected matches the documented primary intent and vessel type.

• Refer to CPT guidance: 37241 for venous malformations/varices/varicoceles, 37242 for arterial non‑hemorrhage, 37243 for tumor/organ ischemia, 37244 for hemorrhage control.
• Only one primary embolization code should be reported per treatment field.

Insufficient documentation may lead to PA denial — include all required elements

Prior-authorization requests lacking required documentation (procedure matching clinical need, condition, conservative treatment details, prior interventions, lesion location/size, nature of CLI, and recent diagnostic imaging/clinical evaluation) may be denied.

• Insufficient documentation of imaging (within 6 months), clinical severity (e.g., CEAP/VCSS), or prior conservative therapy are common triggers for denial.
• Ensure all items from the PVI PA documentation checklist are included to reduce denial risk.

CEA/CAS exclusion: disabling stroke (modified Rankin ≥3) — risk of denial

Carotid revascularization (CEA or CAS) is not medically necessary for individuals who have had a disabling stroke (modified Rankin scale ≥3); authorization requests for such cases risk denial unless life expectancy/benefit considerations are documented.

• Document modified Rankin scale and life-expectancy/benefit rationale for asymptomatic individuals.
• Requests for individuals with modified Rankin ≥3 are considered not medically necessary.

Vertebral artery stenting beyond specified criteria considered experimental — denial risk

Extracranial vertebral artery angioplasty with stent placement is considered experimental/investigational and unproven for indications other than the specified symptomatic criteria; authorization for non‑specified indications may be denied.

• Authorization should be supported by documented symptomatic failure of medical therapy and meeting the specified vertebral stenosis criteria (60–99%) to avoid being considered investigational.
• Asymptomatic vertebral stenosis requests are not supported by the guideline.

Missing CPT‑specific criteria for CPT 34717 (iliac endograft) may cause denial

Absence of documented CPT‑specific criteria (for example, planned concurrent AAA repair, ipsilateral common iliac aneurysm >3.5 cm, and contralateral IIA occlusion for CPT 34717) may trigger denial of requests for iliac endograft procedures.

• For CPT 34717 include explicit documentation of concurrent AAA repair planning, aneurysm size (>3.5 cm), and contralateral IIA occlusion.
• Lack of these elements may result in non-authorization.

CPT 34718 (bifurcated‑bifurcated repair) is experimental — high denial risk

CPT 34718 (bifurcated‑bifurcated aneurysm repair) is categorized as experimental, investigational, and unproven; authorization requests for CPT 34718 may be denied as not medically necessary.

• Do not expect routine coverage for CPT 34718; provide strong evidence if requesting exceptional review.
• Alternate supported approaches should be considered per guideline.

Popliteal aneurysm PA denial risk if size/symptom criteria not met

Requests for endovascular repair of popliteal aneurysms that do not meet size/symptom thresholds (asymptomatic <2.0 cm or symptomatic <1.5 cm without required mural thrombus and ischemic findings) may be denied.

• Asymptomatic repair requires diameter ≥2.0 cm on imaging.
• Symptomatic repair requires diameter ≥1.5 cm PLUS documentation of mural thrombus and ischemic sequelae (new claudication, CLI, or blue toe syndrome).

Visceral aneurysm embolization denial risk if size/vessel criteria not met

Coil embolization for visceral artery aneurysm/pseudoaneurysm that falls outside the listed vessel‑ and size‑specific indications (e.g., hepatic ≥2.0 cm; splenic ≥3.0 cm or any size if child‑bearing potential) may not meet medical necessity and risk denial.

• Provide imaging showing aneurysm measurements meeting the guideline's vessel‑specific thresholds to support authorization.
• Requests outside these thresholds should include compelling clinical justification to avoid denial.

Staging without documented valid justification risks denial

Staging of interventions without documented valid justification in the medical record (patient instability, excess fluoroscopy, unavailable anesthesia resources, or contrast >200 mL) may be denied as not medically necessary.

• Document specific reason(s) for staging in the record to support authorization.
• Absent justification, staged procedures are considered not medically necessary.

Denial risk for non‑indicated infra‑popliteal/asymptomatic interventions (<50% stenosis)

Intervention (PTA or stent) for asymptomatic individuals or for lesions that are not high‑grade/critical (<50%) and routine infrapopliteal/inframalleolar interventions for claudication are not considered medically necessary and are denial triggers.

• Document symptomatic status and objective ≥50% stenosis for interventions; asymptomatic or <50% lesions generally do not meet criteria.
• Routine below‑knee interventions for claudication lack evidence and are typically not authorized.

Renal intervention denial risks when uncontrolled hypertension or transplant criteria not documented

Renal artery interventions lack indication without uncontrolled hypertension; presence of advanced renal disease (hemodialysis) or chronic renal artery occlusion should be documented and may preclude authorization.

• Intervention is indicated when medical therapy fails to control hypertension and imaging confirms renal artery stenosis.
• Requests without uncontrolled hypertension or in hemodialysis patients are unlikely to meet medical necessity.

Saphenous vein PA risk: missing qualifying duplex or CEAP/VCSS documentation

Saphenous vein treatment requests missing a qualifying venous duplex within 6 months demonstrating pathologic truncal vein reflux (≥500 ms) or lacking symptom documentation (CEAP ≥ C2 or VCSS ≥6) risk non‑authorization.

• Ensure duplex within 6 months with segment‑specific reflux documentation (≥500 ms) and CEAP/VCSS scoring are submitted with PA.
• Absence of these items is a common cause for denial.

Denial triggers for non‑compounded foam sclerotherapy: missing CEAP/VCSS or recent duplex; DVT/occlusion present

Treatment requests for non‑compounded foam sclerotherapy lacking documentation of symptomatic reflux (CEAP ≥ C2 or VCSS ≥6) or a venous duplex within 6 months showing required reflux parameters, or with ipsilateral acute DVT or chronic multisegmental femoral‑popliteal occlusion, may be denied.

• Include CEAP/VCSS and duplex showing ≥500 ms truncal reflux per segment requirements for 36465/36466 authorization.
• Contraindications such as ipsilateral acute DVT or chronic multisegmental femoral‑popliteal occlusion should be identified and will preclude treatment.

Missing recent qualifying duplex or presence of ipsilateral DVT/occlusion may cause denial

Absence of documented qualifying venous duplex within 6 months showing required anatomic reflux (e.g., ≥500 ms in required segments) or presence of ipsilateral acute DVT or chronic multisegmental femoral‑popliteal occlusion may trigger denial for venous procedures.

• Ensure duplex studies are recent (≤6 months) and show the exact reflux measurements and segment counts required by the criteria.
• Active ipsilateral DVT or chronic multisegmental occlusion are contraindications and should be documented if present.

Denial risk if recent duplex and CEAP/VCSS not provided for venous PA

Lack of a recent (within 6 months) venous duplex demonstrating required reflux measurements (e.g., ≥500 ms) or absence of required clinical classification (CEAP C2+ or VCSS ≥6) may result in denial for venous interventions.

• Venous duplex recency and CEAP/VCSS are essential elements for authorization of saphenous/truncal vein and sclerotherapy procedures.
• Submit both imaging and clinical severity documentation to reduce likelihood of denial.

Iliac/IVC stenting requires imaging documenting ≥50% area reduction or >60% diameter stenosis — omission risks denial

Iliac/IVC stenting without documentation of ≥50% area reduction or >60% diameter stenosis (or without required associated clinical findings or failed 8‑week conservative therapy) may trigger denial.

• Provide IVUS/venogram/CT/MR demonstrating ≥50% area reduction or >60% diameter stenosis and correlate with clinical sequelae (ulceration, advanced stasis dermatitis, venous claudication, asymmetric edema).
• Document failed 8‑week conservative therapy unless urgent indication exists.

Left renal vein stenting for primary nutcracker treatment is NMN — denial risk

Angioplasty or stenting of the left renal vein for primary treatment of nutcracker syndrome is considered not medically necessary; requests for primary endovascular treatment prior to surgical decompression are usually denied.

• Primary endovascular treatment of left renal vein compression (nutcracker) prior to surgical decompression is NMN.
• Authorization for re‑intervention after prior surgical decompression may be considered when recurrent imaging‑documented compression and symptoms are present.

Prophylactic aortic side branch embolization prior to EVAR is not indicated — denial risk

Embolization of aortic side branches prior to EVAR solely to prevent Type 2 endoleak is not medically necessary; requests for prophylactic embolization for EVAR may be denied.

• Do not submit authorization requests for embolization of lumbar or inferior mesenteric branches purely to prevent Type 2 endoleak.
• If embolization is performed for therapeutic bleeding or other supported indication, include that documentation.

Embolization for non‑listed indications is NMN — expect denial without strong justification

Requests for embolization for indications not listed in this guideline are considered not medically necessary and may be denied; provide evidence‑based justification if pursuing an unlisted indication.

• Embolization is covered for listed organ‑ and condition‑specific indications; unlisted uses lack guideline support.
• Include literature or multisociety guidance only when requesting exceptional consideration for non‑listed indications.

Coding accuracy for embolization (37241–37244) required — incorrect coding risks audit/denial

Incorrect embolization coding (mismatching CPT 37241–37244 to the documented primary intent or vessel type) may trigger audit or denial; ensure coding aligns with the documented clinical intent and operative field.

• Select only one primary embolization code per treatment field based on the dominant therapeutic intent.
• Document vessel type and primary intent clearly in the PA to support selected CPT code(s).